Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
FT819 in Subjects With B-cell Malignancies
- Conditions
- Chronic Lymphocytic LeukemiaLymphoma, B-CellPrecursor B-Cell Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 54
- Registration Number
- NCT04629729
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
- Conditions
- Waldenstrom Macroglobulinemia
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 63
- Registration Number
- NCT04624906
- Locations
- 🇨🇦
McGill University Health Centre, Montréal, Quebec, Canada
🇨🇦QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦CHU de Quebec - University Laval, Laval, Quebec, Canada
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 350
- Registration Number
- NCT04607772
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸US Oncology - Oncology Associates of Oregon, Eugene, Oregon, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- Conditions
- Recurrent Follicular LymphomaRefractory Follicular Lymphoma
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Joseph Tuscano
- Target Recruit Count
- 23
- Registration Number
- NCT04587687
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection
- Conditions
- Indolent B-Cell Non-Hodgkin's Lymphomas
- Interventions
- First Posted Date
- 2020-09-30
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 91
- Registration Number
- NCT04569838
- Locations
- 🇨🇳
Guangxi Medical University Affiliated Tumor Hospital, Nanning, Guangxi, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳First People's Hospital of Foshan, Foshan, Guangdong, China
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients with Relapsed/refractory CLL
- Conditions
- Chronic Lymphoid Leukemia
- Interventions
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 42
- Registration Number
- NCT04515238
- Locations
- 🇩🇪
Onkologische Schwerpunktpraxis, Esslingen, Germany
🇩🇪Hamatologische/Onkologische Gemeinschaftspraxis, Augsburg, Germany
🇩🇪Universitätsklinik Köln, Köln, Germany
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
- Conditions
- Refractory CancerClassical Hodgkin LymphomaRelapsed Cancer
- Interventions
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 37
- Registration Number
- NCT04510636
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 166
- Registration Number
- NCT04285567
- Locations
- 🇺🇸
Medical Center of Aurora, Aurora, Colorado, United States
🇺🇸American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States
🇺🇸University of Tennessee Medical Center;Office of Clinical Trials, Knoxville, Tennessee, United States
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
- Conditions
- Hodgkin Lymphoma, AdultHodgkin Disease RecurrentHodgkin Disease RefractoryHodgkin Disease, Pediatric
- Interventions
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Tessa Therapeutics
- Target Recruit Count
- 97
- Registration Number
- NCT04268706
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
- Conditions
- Lymphoma, B-CellChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 98
- Registration Number
- NCT04245722
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.